Compare Alcon AG (ALC) vs 3M Company (MMM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs 3M Company — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while 3M Company trades at $154.95 (market cap $82.41B). The key difference: 3M Company is far larger — about 2.5× Alcon AG's market cap, and 3M Company pays the higher dividend (1.97%). Which is the better fit depends on your goals.
| ALC | MMM | |
|---|---|---|
Market Cap | $32.69B | $82.41B |
Sector | Health | Industrials |
52-Week High | $92.22 | $174.61 |
52-Week Low | $62.02 | $141.10 |
Enterprise Value | $36.28B | $90.82B |
Dividend Yield | 0.54% | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
MMM trades at $158.00, down 1.52% today, with a bullish technical signal driven by moving averages. The company reported three consecutive quarterly EPS beats, with Q2 2026 results expected on July 21, 2026. Strong profitability metrics include a 72.14% ROE and 11.14% net margin, though revenue has declined from 2022 peaks. Recent news highlights partnerships with Airbus and an AI tool launch, supporting operational momentum.
Outlook is mixed: analyst consensus is a Hold with a $148.75 price target below current levels, citing limited AI exposure. Risks include volatile cash flows and high debt. Upside depends on execution of growth initiatives and margin improvement. The stock offers a dividend yield with the next payment on June 12, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
